Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 344 Shares

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German sold 344 shares of the company’s stock in a transaction on Friday, March 21st. The stock was sold at an average price of $54.23, for a total value of $18,655.12. Following the sale, the chief accounting officer now owns 2,889 shares of the company’s stock, valued at $156,670.47. The trade was a 10.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Christopher Paul German also recently made the following trade(s):

• On Wednesday, February 19th, Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $57.22, for a total value of $36,334.70.

Rhythm Pharmaceuticals Trading Up 3.2 %

Shares of RYTM stock opened at $53.72 on Tuesday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $35.17 and a 1-year high of $68.58. The stock has a market cap of $3.40 billion, a price-to-earnings ratio of -12.41 and a beta of 2.30. The stock has a 50-day moving average of $55.28 and a 200-day moving average of $54.99.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The firm had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Sell-side analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Rhythm Pharmaceuticals in a report on Monday. Canaccord Genuity Group increased their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 target price on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $69.46.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. SRS Capital Advisors Inc. grew its holdings in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter worth approximately $28,000. SBI Securities Co. Ltd. bought a new stake in Rhythm Pharmaceuticals in the fourth quarter worth approximately $37,000. R Squared Ltd acquired a new position in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $44,000. Finally, State of Wyoming bought a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $61,000.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.